SALT LAKE CITY, Nov. 29, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes, today ...
• Activation of nuclear factor erythroid 2-related factor 2 (Nrf2) significantly reduces the accumulation of senescent bronchial epithelial cells in chronic obstructive pulmonary disease (COPD) models ...
C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results